Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Expanded_access × Neoplasms × LY3023414 × Clear all

Status

Sponsor Class

Study Type

Interventional 2 Expanded_access 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Interventions

Bone Marrow Transplantation 2 3-Iodobenzylguanidine 2 vorasidenib 1 tucatinib 1 tovorafenib 1 taletrectinib 1 olaparib 1 nirogacestat 1 glucarpidase 1 enzalutamide 1 denileukin diftitox 1 copanlisib 1 balstilimab 1 atezolizumab 1 adagrasib 1 Proton Pump Inhibitors 1 Peripheral Blood Stem Cell Transplantation 1 Nivolumab 1 LY3023414 1 Hydrocortisone 1 Crizotinib 1 Carboxypeptidases 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02632994 2025-09-29

Master Rollover Protocol for Continued Safety Assessment of Study Drug

Eli Lilly and Company

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡